Product information and disease description Place of product in therapy Approaches to treatment Current treatment options and standard of care

Taxane-Based chemotherapy

4 evidence topics · 4 sources

Addition of nab-paclitaxel to first-line gemcitabine and cisplatin: SWOG S1815 phase 3 trial

“Median OS with GAP was 14.0 months (95% CI, 12.4 to 16.1) and 13.6 months with GC (95% CI, 9.7 to 16.6); hazard ratio (HR), 0.91 (95% CI, 0.72 to 1.14); P = .41.” (opens the source at this quote in a new tab)
“The addition of a taxane in the GAP regimen to the standard gemcitabine-cisplatin regimen did not improve OS in newly diagnosed BTC.” (opens the source at this quote in a new tab)

Paclitaxel use in later-line practice: French single-center series of 256 participants

“Treatment distribution was as follows: FOLFIRI (n = 51, 20%), paclitaxel (n = 43, 17%), combinations of 5-FU cisplatin/FOLFOX (n = 32, 13%), molecularly targeted therapy (n = 65, 25%) and others (n = 63, 25%).” (opens the source at this quote in a new tab)
“OS was 13 months with paclitaxel and 7 months with FOLFIRI (P = 0.03).” (opens the source at this quote in a new tab)

Nab-paclitaxel-based second-line therapy: real-world cohort of 84 participants

“Second-line options for biliary tract cancer (BTC) are limited. While nab-paclitaxel has demonstrated certain antitumor activity, evidence remains scarce.” (opens the source at this quote in a new tab)
“Among 84 patients (41 in the chemo-anti-PD-(L)1 group and 43 in the chemotherapy group), the median OS was 15.17 months (95% confidence interval (CI), 12.63-21.43), median PFS was 5.40 months (95% CI, 3.23-8.03), objective response rate (ORR) was 21.43% (95% CI, 13.22-31.74), and disease control rate (DCR) was 60.71% (95% CI, 49.45-71.20).” (opens the source at this quote in a new tab)

Rationale for paclitaxel as the COMPANION-002 comparator

“Paclitaxel was chosen based on the safety and efficacy data from this phase Ib study.” (opens the source at this quote in a new tab)
“The primary end point of the phase II study was overall response rate (ORR) and the ORR was 37.5% (n = 9/24 patients).” (opens the source at this quote in a new tab)
“Among 11 patients treated in the second-line, the ORR was 63.6% (n = 7/11) versus 15% (n = 2/13) among patients treated in the third-line setting.” (opens the source at this quote in a new tab)